argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
argenx (Nasdaq: ARGX) has announced a partnership with nine-time Grand Slam champion Monica Seles to raise awareness for myasthenia gravis (MG). For the first time, Seles is publicly sharing her 5-year journey with MG, a chronic autoimmune disease affecting over 120,000 people in the U.S.
The partnership will highlight the company's 'Go for Greater' MG patient support initiative at the 2025 U.S. Open Tennis Championships, where argenx serves as a premier Global sponsor. The initiative aims to connect MG patients with support resources and foster community engagement through the website mg-united.com.
argenx (Nasdaq: ARGX) ha annunciato una collaborazione con Monica Seles, vincitrice di nove titoli del Grande Slam, per sensibilizzare sulla miastenia gravis (MG). Per la prima volta, Seles condivide pubblicamente il suo percorso di 5 anni con la MG, una malattia autoimmune cronica che colpisce oltre 120.000 persone negli Stati Uniti.
La partnership metterà in luce l'iniziativa di supporto ai pazienti 'Go for Greater' per la MG durante gli US Open di tennis 2025, dove argenx è sponsor globale principale. L'iniziativa punta a mettere in contatto i pazienti con risorse di supporto e a favorire il coinvolgimento della comunità attraverso il sito mg-united.com.
argenx (Nasdaq: ARGX) ha anunciado una asociación con Monica Seles, campeona de Grand Slam en nueve ocasiones, para concienciar sobre la miastenia gravis (MG). Por primera vez, Seles comparte públicamente su trayectoria de 5 años con la MG, una enfermedad autoinmune crónica que afecta a más de 120.000 personas en EE. UU.
La colaboración destacará la iniciativa de apoyo a pacientes con MG 'Go for Greater' en el US Open de tenis 2025, donde argenx actúa como patrocinador global principal. La iniciativa pretende conectar a pacientes con recursos de apoyo y fomentar la participación de la comunidad a través del sitio mg-united.com.
argenx (나스닥: ARGX)는 그랜드슬램 9회 우승자 모니카 셀레스와 협력해 중증 근무력증(MG)에 대한 인식을 높이기로 했습니다. 셀레스는 처음으로 MG와 함께한 5년의 여정을 공개하며, 이 만성 자가면역 질환은 미국에서 12만 명이 넘는 사람들에게 영향을 미칩니다.
이번 파트너십은 argenx가 프리미어 글로벌 스폰서로 참여하는 2025년 US 오픈 테니스 대회에서 'Go for Greater' MG 환자 지원 프로그램을 부각할 예정입니다. 이 프로그램은 환자들이 지원 자원과 연결되고 공동체 참여를 촉진하도록 mg-united.com을 통해 운영됩니다.
argenx (Nasdaq: ARGX) a annoncé un partenariat avec Monica Seles, championne de Grand Chelem à neuf reprises, pour sensibiliser à la myasthénie grave (MG). Pour la première fois, Seles partage publiquement son parcours de cinq ans avec la MG, une maladie auto-immune chronique touchant plus de 120 000 personnes aux États-Unis.
Le partenariat mettra en avant l'initiative d'accompagnement des patients atteints de MG 'Go for Greater' lors des US Open de tennis 2025, où argenx est sponsor mondial principal. L'initiative vise à connecter les patients MG avec des ressources de soutien et à favoriser l'engagement communautaire via le site mg-united.com.
argenx (Nasdaq: ARGX) hat eine Partnerschaft mit der neunmaligen Grand-Slam-Siegerin Monica Seles angekündigt, um auf Myasthenia gravis (MG) aufmerksam zu machen. Zum ersten Mal teilt Seles öffentlich ihre fünfjährige Erfahrung mit MG, einer chronischen Autoimmunerkrankung, die in den USA mehr als 120.000 Menschen betrifft.
Die Partnerschaft stellt die 'Go for Greater'-Patientenunterstützungsinitiative für MG bei den US Open Tennis Championships 2025 in den Mittelpunkt, bei denen argenx als globaler Hauptsponsor fungiert. Ziel der Initiative ist es, MG-Patienten mit Unterstützungsangeboten zu vernetzen und das Engagement der Gemeinschaft über die Website mg-united.com zu fördern.
- Partnership with high-profile tennis champion Monica Seles increases disease awareness and brand visibility
- Premier Global sponsorship of 2025 U.S. Open provides significant marketing exposure
- None.
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life
Partnership with Seles will highlight the ‘Go for Greater’ MG patient support initiative at the 2025 U.S. Open Tennis Championships
August 12, 2025 6:45 AM EDT
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced a partnership with nine-time Grand Slam tennis champion Monica Seles. For the first time ever, Seles is publicly speaking out about her experience with myasthenia gravis (MG) in support of argenx’s Go for Greater initiative. The partnership aims to raise awareness and understanding of MG, and connect those affected with available tools and support resources.
“My MG journey over the past 5 years has not been an easy one. I felt isolated and defeated as many of the activities I enjoyed were no longer physically possible for me. I’ve since realized that by sharing my story, I can raise awareness of this disease, empower patients to advocate for themselves and help them connect with the MG community for support,” said Monica Seles. “I am excited to partner with the argenx team – to inspire others living with MG to rally against this disease, pursue their goals, and live a fulfilling life. We’re all in this together.”
“At argenx, we are committed to supporting the MG community by fostering understanding and connection,” said Karen Massey, Chief Operating Officer, argenx. “We applaud Monica for sharing her personal story and are excited to collaborate with her to amplify the voices of MG patients and caregivers. Her journey and dedication to this cause will help people living with MG engage in meaningful conversations and build a supportive network around this challenging disease. Together, we hope to shine a light of understanding and support for those affected by MG.”
argenx has a long-standing commitment to the MG community, helping to empower patients through programs such as Go for Greater. This program supports patients in achieving a greater quality of living by fostering connections between real people with MG, and offering support and helpful resources. In addition to the new partnership with Seles, argenx is a premier Global sponsor of the upcoming 2025 U.S. Open to amplify awareness of MG on a global stage.
In the U.S., over 120,000 people are living with MG, an autoimmune, neuromuscular condition that causes a variety of symptoms, including weakness in the arms and legs, fatigue, difficulty walking, and blurred and double vision.
For more information about the Go for Greater campaign, visit www.mg-united.com.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media contact for argenx:
Ben Petok
bpetok@argenx.com
Media contact for Real Chemistry:
Ashley Cohen
ascohen@realchemistry.com
Attachments
